|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
UA75049C2
(uk)
|
1999-08-17 |
2006-03-15 |
Байоджен Айдек Ма Інк. |
Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US20030012783A1
(en)
|
2001-02-20 |
2003-01-16 |
Wayne Kindsvogel |
Antibodies that bind both BCMA and TACI
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
DE10328289B3
(de)
|
2003-06-23 |
2005-01-05 |
Enginion Ag |
Arbeitsmedium für Dampfkreisprozesse
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7491390B2
(en)
|
2004-10-15 |
2009-02-17 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
US20120294863A1
(en)
|
2004-10-15 |
2012-11-22 |
Seattle Genetics, Inc. |
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
|
|
US7641903B2
(en)
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
EP1827604B1
(en)
|
2004-12-10 |
2019-11-20 |
Peter MacCallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
|
CN103145839A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
CA2623236A1
(en)
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Human monoclonal antibodies to cd70
|
|
KR20090088946A
(ko)
*
|
2006-12-14 |
2009-08-20 |
메다렉스, 인코포레이티드 |
씨디70에 결합하는 인간 항체 및 이의 용도
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
WO2009033095A2
(en)
|
2007-09-07 |
2009-03-12 |
Cisthera, Incorporated |
Humanized pai-1 antibodies
|
|
EP2276509B1
(en)
|
2008-04-11 |
2016-06-15 |
Seattle Genetics, Inc. |
Detection and tratment of pancreatic, ovarian and other cancers
|
|
KR20110039220A
(ko)
|
2008-06-30 |
2011-04-15 |
교와 핫꼬 기린 가부시키가이샤 |
항ｃｄ27 항체
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
HUE041436T2
(hu)
|
2009-12-10 |
2019-05-28 |
Univ Minnesota |
Tal-effektor-közvetített DNS-módosítás
|
|
EP2520589B1
(en)
|
2009-12-29 |
2018-11-07 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
CN108424462A
(zh)
|
2010-10-27 |
2018-08-21 |
贝勒医学院 |
使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
DK2686347T3
(en)
|
2011-03-16 |
2018-06-25 |
Argenx Bvba |
Antibodies against CD70
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
AU2012335205A1
(en)
|
2011-11-11 |
2014-05-29 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
KR20130060720A
(ko)
|
2011-11-30 |
2013-06-10 |
한국전자통신연구원 |
목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법
|
|
WO2013138586A1
(en)
|
2012-03-15 |
2013-09-19 |
Janssen Biotech, Inc. |
Human anti-cd27 antibodies, methods and uses
|
|
EA033110B1
(ru)
|
2012-04-11 |
2019-08-30 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
JP6694712B2
(ja)
|
2012-11-01 |
2020-05-20 |
マックス−デルブルック−セントラム フアー モレキュラーレ メデジン |
Ｃｄ２６９（ｂｃｍａ）に対する抗体
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
WO2014158821A1
(en)
|
2013-03-12 |
2014-10-02 |
Imaginab, Inc. |
Antigen binding constructs to cd70
|
|
EA201591710A1
(ru)
|
2013-03-13 |
2016-03-31 |
Сиэтл Дженетикс, Инк. |
Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
JP6346266B2
(ja)
|
2013-03-21 |
2018-06-20 |
サンガモ セラピューティクス， インコーポレイテッド |
操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
US20160296562A1
(en)
|
2013-11-21 |
2016-10-13 |
Ucl Business Plc |
Cell
|
|
JP2017505819A
(ja)
|
2014-02-04 |
2017-02-23 |
カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ |
Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
|
|
ES3063961T3
(en)
*
|
2014-02-14 |
2026-04-21 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
CA2940460A1
(en)
|
2014-03-07 |
2015-09-11 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015158671A1
(en)
|
2014-04-14 |
2015-10-22 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2945335A1
(en)
*
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
KR20160145802A
(ko)
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
|
|
MX383150B
(es)
|
2014-06-02 |
2025-03-13 |
Us Health |
Receptores quiméricos de antígeno que tienen como diana a cd-19.
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
MX2017001229A
(es)
|
2014-07-29 |
2017-05-01 |
Pfizer |
Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
|
|
WO2016025454A2
(en)
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
AU2015357526B2
(en)
|
2014-12-05 |
2022-03-17 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
|
|
CN113968913A
(zh)
*
|
2014-12-08 |
2022-01-25 |
美国卫生和人力服务部 |
抗cd70嵌合抗原受体
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
BR112017013176A2
(en)
|
2014-12-19 |
2018-05-15 |
Dana-Farber Cancer Institute Inc. |
chimeric antigen receptors and methods for using them
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
KR20260048600A
(ko)
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
CN104910278B
(zh)
|
2015-05-27 |
2018-05-25 |
上海吉凯基因科技有限公司 |
一种用于制备cart细胞的具有高效转染能力和生物学活性的慢病毒
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
CN117070468A
(zh)
|
2015-10-05 |
2023-11-17 |
精密生物科学公司 |
包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
|
|
GB201518136D0
(en)
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
JP7115982B2
(ja)
|
2015-10-30 |
2022-08-09 |
アレタ・バイオセラピューティクス・インコーポレイテッド |
癌の治療のための組成物及び方法
|
|
CA3005042A1
(en)
|
2015-11-13 |
2017-05-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-bcma polypeptides and proteins
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
EP3988655A3
(en)
|
2015-12-23 |
2022-08-03 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
ITUB20160112A1
(it)
|
2016-01-28 |
2016-04-28 |
Serteaweb Srl |
Processo di allarme e sistema televisivo relativo ad un tale processo di allarme
|
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
MX2018010924A
(es)
|
2016-03-11 |
2019-02-13 |
Bluebird Bio Inc |
Células efectoras inmunitarias con edición genómica.
|
|
CN109219445B
(zh)
|
2016-04-01 |
2022-08-26 |
上海煦顼技术有限公司 |
嵌合抗原受体修饰细胞治疗癌症的应用
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
CN109415687A
(zh)
|
2016-04-07 |
2019-03-01 |
蓝鸟生物公司 |
嵌合抗原受体t细胞组合物
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
WO2017182608A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
|
US11141471B2
(en)
*
|
2016-04-25 |
2021-10-12 |
Regen BioPharma, Inc. |
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
SG10202012157QA
(en)
|
2016-06-07 |
2021-01-28 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CN106544321B
(zh)
|
2016-10-13 |
2019-01-29 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018068257A1
(zh)
|
2016-10-13 |
2018-04-19 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
JP7717439B2
(ja)
|
2017-01-10 |
2025-08-04 |
ザ ジェネラル ホスピタル コーポレイション |
修飾されたｔ細胞及びその使用方法
|
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
WO2019119036A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Benitec Biopharma Limited |
Cd70 deficient cells, and methods and reagents for producing same
|
|
KR102780406B1
(ko)
|
2018-02-01 |
2025-03-17 |
화이자 인코포레이티드 |
Cd70을 표적으로 하는 키메라 항원 수용체
|
|
US11957695B2
(en)
*
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|